CD274 and adenocarcinoma: Within gastric and gastroesophageal junction (GEJ) adenocarcinomas, the totality of the frontline data suggests that patients with a PD-L1 CPS of less than 5 derive no benefit from the addition of anti-PD-1 antibodies to standard chemotherapy.